| Identification | Back Directory | [Name]
N-[4-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3-yl)phenyl]-4-phenylbenzamide | [CAS]
1005304-44-8 | [Synonyms]
SARS-CoV-2 nsp13-IN-1
N-[4-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3-yl)phenyl]-4-phenylbenzamide
[1,1'-Biphenyl]-4-carboxamide, N-[4-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)phenyl]- | [Molecular Formula]
C27H20N4O2 | [MOL File]
1005304-44-8.mol | [Molecular Weight]
432.47 |
| Hazard Information | Back Directory | [Uses]
SARS-CoV-2 nsp13-IN-1 (compound C1) is a potent nsp13 (non-structural protein 13) inhibitor. SARS-CoV-2 nsp13-IN-1 only inhibits nsp13 ssDNA+ ATPase, with an IC50 of 6 μM. SARS-CoV-2 nsp13-IN-1 does not inhibit ssDNA- ATPase. SARS-CoV-2 nsp13-IN-1 can be used for COVID-19 research[1]. | [References]
[1] Yazdi AK, et al. Kinetic Characterization of SARS-CoV-2 nsp13 ATPase Activity and Discovery of Small-Molecule Inhibitors. ACS Infect Dis. 2022 Jul 13. DOI:10.1021/acsinfecdis.2c00165 |
|
|